Liposomal Vitamin C

Likely achieves higher blood levels than standard oral vitamin C, but whether this translates to clinically meaningful advantages is unproven for most applications.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Pharmacokinetic studies show liposomal vitamin C produces higher peak and AUC plasma levels than standard oral vitamin C. One study found liposomal vitamin C achieved ~70% of IV levels. However, clinical outcome studies comparing liposomal to standard oral vitamin C are lacking.

• Higher oral bioavailability than standard vitamin C
• Reduced GI side effects compared to high-dose standard forms
• May be useful when higher plasma levels are desired without IV access

Typical doses: 500-2000 mg daily. The liposomal encapsulation may allow lower total doses to achieve similar plasma levels as higher standard oral doses.

• Generally well-tolerated
• Mild GI effects less common than standard high-dose vitamin C
• Kidney stone risk at very high chronic doses

More expensive than standard vitamin C. Liposome quality varies between manufacturers. High doses still carry risk of kidney stones in susceptible individuals.

Superior pharmacokinetics do not guarantee superior clinical outcomes. Standard vitamin C at 200-400 mg achieves near-maximal tissue saturation. The additional bioavailability may only matter for supra-physiological dosing strategies.

• Immunity55
• Longevity40